Literature DB >> 28685759

Parkinson disease: Defining PD subtypes - a step toward personalized management?

Caroline H Williams-Gray1, Roger A Barker1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28685759     DOI： 10.1038/nrneurol.2017.98

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

Review 1.  The heterogeneity of idiopathic Parkinson's disease.

Authors:  Thomas Foltynie; Carol Brayne; Roger A Barker
Journal:  J Neurol       Date:  2002-02       Impact factor: 4.849

Review 2.  The identification of Parkinson's disease subtypes using cluster analysis: a systematic review.

Authors:  Stephanie M van Rooden; Willem J Heiser; Joost N Kok; Dagmar Verbaan; Jacobus J van Hilten; Johan Marinus
Journal:  Mov Disord       Date:  2010-06-15       Impact factor: 10.338

3.  Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease.

Authors:  Roberto Erro; Marina Picillo; Carmine Vitale; Raffaele Palladino; Marianna Amboni; Marcello Moccia; Maria Teresa Pellecchia; Paolo Barone
Journal:  Parkinsonism Relat Disord       Date:  2016-04-28       Impact factor: 4.891

4.  Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Authors:  Ganqiang Liu; Joseph J Locascio; Jean-Christophe Corvol; Brendon Boot; Zhixiang Liao; Kara Page; Daly Franco; Kyle Burke; Iris E Jansen; Ana Trisini-Lipsanopoulos; Sophie Winder-Rhodes; Caroline M Tanner; Anthony E Lang; Shirley Eberly; Alexis Elbaz; Alexis Brice; Graziella Mangone; Bernard Ravina; Ira Shoulson; Florence Cormier-Dequaire; Peter Heutink; Jacobus J van Hilten; Roger A Barker; Caroline H Williams-Gray; Johan Marinus; Clemens R Scherzer
Journal:  Lancet Neurol       Date:  2017-06-16       Impact factor: 44.182

5.  Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.

Authors:  Seyed-Mohammad Fereshtehnejad; Yashar Zeighami; Alain Dagher; Ronald B Postuma
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

6.  Development and external validation of a prognostic model in newly diagnosed Parkinson disease.

Authors:  Daan C Velseboer; Rob M A de Bie; Luuk Wieske; Jonathan R Evans; Sarah L Mason; Thomas Foltynie; Ben Schmand; Rob J de Haan; Bart Post; Roger A Barker; Caroline H Williams-Gray
Journal:  Neurology       Date:  2016-02-17       Impact factor: 9.910

7.  A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes.

Authors:  J M Graham; H J Sagar
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

8.  Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

Authors:  S J G Lewis; T Foltynie; A D Blackwell; T W Robbins; A M Owen; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

Review 9.  The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease.

Authors:  Lucy M Collins; Caroline H Williams-Gray
Journal:  Front Psychiatry       Date:  2016-05-20       Impact factor: 4.157

10.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study.

Authors:  Thomas Foltynie; Carol E G Brayne; Trevor W Robbins; Roger A Barker
Journal:  Brain       Date:  2003-12-22       Impact factor: 13.501
  10 in total
  3 in total

Review 1.  Therapies to Slow, Stop, or Reverse Parkinson's Disease.

Authors:  Tom Foltynie; J William Langston
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

Review 2.  Subtyping of Parkinson's Disease - Where Are We Up To?

Authors:  Elizabeth Qian; Yue Huang
Journal:  Aging Dis       Date:  2019-10-01       Impact factor: 6.745

3.  Clinical classification systems and long-term outcome in mid- and late-stage Parkinson's disease.

Authors:  Emil Ygland Rödström; Andreas Puschmann
Journal:  NPJ Parkinsons Dis       Date:  2021-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.